Pro Medicus (ASX:PME) shares increased by a record 7.7% to A$74.99.

This marks the company’s biggest intraday percentage gain since November 11, 2022.

The healthcare company reported a 36.5% increase in net profit for the fiscal year to A$60.6 million, in alignment with estimates from Jefferies.

Revenue from contracts also soared nearly 34% to A$124.9 million.

Jefferies predicts an optimistic future for Pro Medicus, pointing to the prospects of their imaging technology arm, Visage 7, in North America.

Pro Medicus also declared an end-of-year dividend of 17 AU cents per share.

The company’s stock has risen by 26% this year to date.

Pro Medicus is a healthcare company specializing in medical imaging products and services.